The Ideal Protein Weight Loss Protocol:
Findings of an analysis of 233 patients on the Ideal Protein Weight Loss Protocol over 12 weeks were presented at the 9th Annual Obesity Summit at the Cleveland Clinic, and at the Annual Scientific Meeting of the National Obesity Society. The results show safe, effective weight loss, and as a result of the weight loss reduction of risk factors for cardiovascular disease. Doctors report that weight loss resulting from the Ideal Protein Weight Loss Protocol help reduce hypertension, insulin imbalance, and other heart risks; improve lipid profiles and other risk factors associated with metabolic syndrome; and are measurable and sustainable.
Ideal Protein Weight Loss Protocol is medically designed and developed and is consistent with evidence-based guidelines for weight loss management and maintenance. It is a weight loss solution for the obese and overweight patient, including those with metabolic syndrome.
The Ideal Protein Weight Loss Protocol is a proven, three-phase approach that enables safe, effective weight loss, with a healthy lifestyle approach and a structured maintenance program to sustain weight loss success. The Protocol, which is offered through health care practitioners' offices, targets the root causes of weight gain by reversing the imbalance of insulin that occurs with the typical Western diet. A healthier lifestyle education is a key component of all phases of the Ideal Protein Weight Loss Protocol, which features personalized, one-on-one coaching and a diet plan to promote losing fat while protecting lean muscle mass.
For the practice, the Ideal Protein Weight Loss Protocol is a comprehensive turnkey program with no costs for training and implementation, and no long-term commitment. Learn more at idealprotein.com.
A randomized controlled trial published in Obesity Science and Practice, led by Tulane University, compared the Ideal Protein dietary behavioral intervention (IP system), to a standard, guideline-based, low-calorie, low-fat (LCLF) dietary behavioral intervention.
A randomized controlled trial, led by the University of British Columbia, published in Nature Communications, evaluates the impact of a pharmacist-led therapeutic carbohydrate restricted diet (Pharm-TCR) on type 2 diabetes (T2D).